Loading...
New developments in the treatment of metastatic melanoma – role of dabrafenib–trametinib combination therapy
Development of selective inhibitors of BRAF has improved the survival of patients with BRAF-mutant melanoma. The progression-free survival after treatment with a BRAF inhibitor is modest, however, and BRAF inhibitors induce cutaneous toxicity, likely due to paradoxical activation of the mitogen-acti...
Na minha lista:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Dove Medical Press
2014
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4075957/ https://ncbi.nlm.nih.gov/pubmed/25018652 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DHPS.S39568 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|